The FDA issued a complete response letter for SYD-101, citing insufficient evidence of effectiveness despite achieving ...

Broadwood Partners, STAAR's largest shareholder, opposes the Alcon merger, citing board conflicts and rushed decision-making.

Glaukos recently obtained FDA clearance for Epioxa, a topical, incision-free therapy for keratoconus that preserves the ...

Nanoscope Therapeutics has released positive 3-year follow-up data from its REMAIN study, the long-term extension of the ...

According to Chang, these findings suggest that “OTX-TKI has more widespread effects on overall retinal leakage and ...

Functional vision improvements are reported, with optimal pupil size considerations for varying light conditions being ...

This case, Singh notes, has profoundly influenced his philosophy of glaucoma management: balancing surgical risk with the ...

Researchers from New York Eye and Ear Infirmary of Mount Sinai, New York, reported that subretinal drusenoid deposits (SDDs) ...

Luis Arias, MD; and Paolo Lanzetta, MD, recently found themselves on opposite sides of the debate table regarding the value ...

Their discussion sheds light on the importance of physician advocacy in ophthalmology—from shaping policy and protecting patients to building community.

Glaukos announced that the FDA has approved the new drug application for its topical drug therapy (Epioxa HD/Epioxa) for ...

Stoke Therapeutics announced 2-year data from the FALCON study, a prospective natural history study in people with autosomal ...